U.S. Office REITs Stock News

NYSE:NPO
NYSE:NPOMachinery

Enpro 3.0 Acquisition Pipeline Targets Growth While Valuation Raises Questions

Enpro (NYSE:NPO) has outlined a robust pipeline of acquisitions under its Enpro 3.0 strategy. The plan focuses on adding capabilities in key growth areas and adjusting the company’s business mix. The company aims to use disciplined M&A to support its strategic objectives through 2030. For you as an investor, the message is that Enpro wants to be more focused on areas it views as higher opportunity, rather than simply getting bigger for its own sake. By targeting businesses that fit its...
NYSE:PK
NYSE:PKHotel and Resort REITs

A Look At Park Hotels & Resorts (PK) Valuation After Results, Guidance, Dividend Update And New COO Appointment

Park Hotels & Resorts (PK) shares are back in focus after the company reported fourth quarter and full year 2025 results, paired with fresh 2026 guidance, a leadership change, and a reaffirmed cash dividend. See our latest analysis for Park Hotels & Resorts. The latest results, dividend affirmation and the appointment of Sean Dell’Orto as COO come as Park Hotels & Resorts trades near US$11.27, with a 90 day share price return of 4.06% and a 3 year total shareholder return of 13.70%. This...
NasdaqGS:KDP
NasdaqGS:KDPBeverage

Keurig Dr Pepper (KDP) Margins Improve To 12.5% Net Profit Challenging Coffee Weakness Concerns

Keurig Dr Pepper (KDP) has wrapped up FY 2025 with fourth quarter revenue of US$4.5 billion and basic EPS of US$0.26, setting the tone for how investors assess the full year. The company has seen quarterly revenue move from US$4.1 billion in Q4 2024 to US$4.5 billion in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 to EPS of US$0.26 over the same period, against a trailing twelve month EPS of US$1.53. With trailing net margin at 12.5% and earnings growth highlighted over the...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

Evaluating CorMedix (CRMD) Valuation As Melinta Acquisition And DefenCath Outlook Refocus Investor Attention

Why CorMedix (CRMD) is on investors’ radar now CorMedix (CRMD) has drawn fresh attention after a period where the share price showed mixed short term performance, with a small 1 day gain contrasting with weaker month and past 3 months returns. See our latest analysis for CorMedix. At a share price of US$7.07, CorMedix has seen a 1 day share price return of 0.86%. The 90 day share price return of 26.74% and year to date share price return of 41.86% indicate fading momentum compared with the...
NasdaqGS:SHOO
NasdaqGS:SHOOLuxury

Steven Madden (SHOO) Is Down 5.2% After Margin-Squeezing 2025 Results and Withheld Profit Outlook

Steven Madden, Ltd. has reported its fourth-quarter and full-year 2025 results, with revenue rising to US$753.7 million in the quarter and US$2.53 billion for the year, while net income dropped to US$23.19 million for the quarter and US$44.66 million for the year, alongside a US$6.30 million trademark impairment, new 2026 revenue growth guidance, a maintained US$0.21 quarterly dividend, and completion of its long-running share repurchase program. The combination of stronger top-line growth...
NYSE:KO
NYSE:KOBeverage

Is Coca-Cola (KO) Priced Fairly After Strong Multi Year Share Price Performance

If you are wondering whether Coca-Cola's share price still lines up with its underlying value, you are not alone. That is exactly what this article aims to unpack. Coca-Cola's stock last closed at US$80.72, with reported returns of 1.5% over 7 days, 10.8% over 30 days, 16.8% year to date and 16.2% over 1 year, as well as 48.4% over 3 years and 87.3% over 5 years. Recent coverage around Coca-Cola has focused on its position as a global consumer staples brand and how investors treat it as a...
NYSE:MAS
NYSE:MASBuilding

Masco Weighs Growth Options As Plumbing And Behr Brands Hold Steady

Masco (NYSE:MAS) is working through a period of flat organic revenue and earnings growth while leaning more heavily on its plumbing and decorative brands. The company is focusing on core products such as Behr paint and plumbing fixtures, which are tied to ongoing home renovation activity. Management attention is turning to potential acquisitions or business adjustments to reaccelerate overall expansion. For you as an investor, the story around Masco (NYSE:MAS) right now is less about...
NasdaqGS:DPZ
NasdaqGS:DPZHospitality

Domino’s Longtime Director Retirement Puts Capital Allocation In Focus

Domino's Pizza (NasdaqGS:DPZ) announced the retirement of longtime board director James A. Goldman. Goldman is stepping down after more than 15 years of service on the company's Board of Directors. His departure marks a change in Domino's corporate governance and board composition. Domino's Pizza, traded on the NasdaqGS under the ticker DPZ, is a global pizza delivery and carryout chain that depends heavily on brand consistency, franchise relationships and technology for ordering and...
NYSE:PRKS
NYSE:PRKSHospitality

Will Earnings After Attendance Slump And Buybacks Change United Parks & Resorts' (PRKS) Narrative

In recent months, United Parks & Resorts has faced weaker attendance and revenue pressure, while authorizing a US$500 million share repurchase program and preparing to report quarterly earnings after a prior revenue miss. Investor focus has intensified after Breach Inlet Capital Management exited its US$13.65 million position, highlighting questions about how buybacks and operational changes might counter ongoing demand and pricing challenges. We’ll now examine how the upcoming earnings...
NasdaqGS:FSLR
NasdaqGS:FSLRSemiconductor

First Solar Weighs Trade Rulings And Perovskite Deal In Growth Plans

U.S. Supreme Court ruling against reciprocal tariffs and new Department of Commerce countervailing duties on certain Asian solar imports reshape trade terms for U.S. solar makers. First Solar announces a patent licensing agreement focused on advanced perovskite solar technology, aiming to broaden its next generation product toolkit. The company expands its U.S. manufacturing footprint, seeking to align production with changing trade rules and domestic demand. For investors watching...
NYSE:ATEN
NYSE:ATENSoftware

A Look At A10 Networks (ATEN) Valuation After Analyst Upgrades And AI Security Growth Outlook

Recent analyst reports on A10 Networks (ATEN) have spotlighted higher earnings estimates and a firm consensus view, with management tying its growth targets to demand for AI related security and networking infrastructure. See our latest analysis for A10 Networks. At a share price of US$18.99, A10 Networks has seen an 11.8% 90 day share price return and a 9.3% 30 day share price return, while the 1 year total shareholder return of a 4.4% decline contrasts with a 5 year total shareholder return...
NYSE:OC
NYSE:OCBuilding

Owens Corning (OC) Valuation Check After Recent Share Price Weakness

Owens Corning overview after recent performance shifts Owens Corning (OC) has drawn fresh attention after recent share price moves, with a 1 day return of 2.12% decline and a 5.19% decline over the past week prompting investors to reassess the stock. Those short term moves contrast with a 1.80% gain over the past month and a 13.51% return in the past 3 months, alongside a 10.93% return year to date and a 18.58% decline over the past year. See our latest analysis for Owens Corning. For Owens...
NYSE:CPAY
NYSE:CPAYDiversified Financial

The Bull Case For Corpay (CPAY) Could Change Following New High-Profile Sports FX Partnerships – Learn Why

In February 2026, Corpay, Inc. announced that its Cross-Border business became Pramac Racing's Official Commercial FX Partner and Premium Partner, while also extending its exclusive multi-year agreement as LIV Golf's Official Corporate FX Provider to support their global payments and currency risk management. These sports-sector partnerships highlight how Corpay is using high-visibility teams and leagues to showcase its cross-border payments platform and FX risk solutions to a global...
NYSE:BOX
NYSE:BOXSoftware

Is Box (BOX) Starting To Look Attractive After A 31% Share Price Slide?

Investors may be wondering if Box is starting to look like a value opportunity after a rough patch, or if the market is rightly cautious about the stock at around US$22.82. The share price has been under pressure, with a 0.6% move over the last week, a 13.8% decline over 30 days, a 20.8% decline year to date, and a 31.1% decline over the past year. However, the 5 year return sits at 21.7%. Recent coverage around Box has focused on its position as a listed software player and how investors...
NasdaqGS:LITE
NasdaqGS:LITECommunications

Lumentum Holdings (LITE) Is Up 14.6% After Surging AI Orders Reshape Growth And Balance Sheet Narrative

In recent weeks, Lumentum reported very strong Q2 results driven by AI data center demand, highlighted over 85% year-over-year revenue growth, and disclosed an order backlog for optical circuit switches exceeding $400 million alongside capacity expansion plans extending into 2027. At the same time, the company revealed a multi-hundred-million-dollar co-packaged optics order for 2027 delivery and flagged going-concern risks tied to potential simultaneous conversions of its convertible notes,...
NYSE:CTS
NYSE:CTSElectronic

A Look At CTS (CTS) Valuation After Recent Share Price Moves And Modest Undervaluation Estimate

CTS overview and recent performance context CTS (CTS) has been drawing attention after recent trading moves, with the stock closing at $52.94. For context, the shares show a 1 day gain of 1.4% but a 7 day decline of 5.5%. Over the past month, CTS has returned 6.5%, and about 24.3% in the past 3 months. On a longer view, total return stands at 20.7% year to date, 17.5% over 1 year, 23.6% over 3 years, and 68.3% across 5 years. See our latest analysis for CTS. The recent 1 day share price gain...
NYSE:BBAI
NYSE:BBAIIT

BigBear.ai Acquires Ask Sage And Deepens Defense Focused AI Ambitions

BigBear.ai Holdings (NYSE:BBAI) closed its $250 million acquisition of Ask Sage, a generative AI platform focused on defense and intelligence users. The deal brings Ask Sage’s generative AI tools into BigBear.ai’s portfolio, targeting national and border security use cases. Management highlights that the acquisition, combined with a large contract backlog, provides greater financial flexibility and revenue visibility. For you as an investor, the Ask Sage deal places BigBear.ai more squarely...
NasdaqGS:THRM
NasdaqGS:THRMAuto Components

Why Gentherm (THRM) Is Up 8.5% After Soft Q4 Profit But Strong 2026–2027 Revenue Outlook

In February 2026, Gentherm reported fourth‑quarter 2025 earnings showing net income falling to US$2.99 million from US$15.32 million a year earlier, while quarterly revenue of about US$382.79 million came in ahead of expectations. Alongside weaker profitability, Gentherm issued product revenue guidance of US$1.5 billion to US$1.6 billion for 2026 and US$1.7 billion for 2027, highlighting its ambition to grow beyond automotive into medical and other precision thermal applications. We’ll now...
NasdaqGS:ATRO
NasdaqGS:ATROAerospace & Defense

Is It Too Late To Consider Astronics (ATRO) After A 298% One Year Rally?

If you are looking at Astronics and wondering whether the recent excitement lines up with the underlying value, this article is going to walk through the key numbers that matter for you. The stock last closed at US$79.39, with returns of 3.1% over 7 days, 4.0% over 30 days, 40.2% year to date and 297.7% over the past year. The 3 year and 5 year returns are 420.9% and 409.6% respectively. These returns sit against a backdrop of ongoing news flow around Astronics' role in the capital goods...
NYSE:APH
NYSE:APHElectronic

Evaluating Amphenol (APH) After Strong Q4 Earnings Beat And Upbeat Guidance

Why Amphenol’s latest earnings are drawing fresh attention Amphenol (APH) is back in focus after reporting Q4 results that exceeded analyst expectations on both revenue and profitability, along with guidance for the next quarter that also came in ahead of forecasts. The company closed 2025 with record Q4 and full year sales, as well as adjusted diluted EPS that management said were significantly above the high end of prior guidance. This highlighted strong demand across its connector and...
NYSE:KR
NYSE:KRConsumer Retailing

Kroger (KR) Valuation Check As New CEO Greg Foran Takes Over And Cost Cuts Accelerate

Kroger (KR) has drawn fresh attention after appointing former Walmart executive Greg Foran as CEO, following an ethics related departure. The company is pressing ahead with cost cuts, corporate restructuring, and selective store and fulfillment center closures. See our latest analysis for Kroger. Those management changes and cost initiatives sit against a share price of US$69.76, with a 30 day share price return of 8.6% and a 5 year total shareholder return of 138.3%, suggesting longer term...
NYSE:WWW
NYSE:WWWLuxury

Is Wolverine World Wide (WWW) Pricing Lagging Its Recent Share Price Recovery

If you are wondering whether Wolverine World Wide at around US$17.58 is offering real value or just looks cheap on the surface, you are not alone. The stock has pulled back over the short term, with a 2.9% decline over 7 days and a 2.4% decline over 30 days, yet it still shows a 19.7% return over 1 year and 14.4% over 3 years, compared with a 42.3% decline over 5 years. Recent attention on Wolverine World Wide has focused on its long term share price pattern. The stronger 1 year and 3 year...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

Why GeneDx Holdings (WGS) Is Down 11.3% After Reaffirming 2026 Guidance And Narrowing 2025 Losses

In February 2026, GeneDx Holdings Corp. reported full-year 2025 results showing revenue of US$427.54 million versus US$305.45 million in 2024, alongside a narrower net loss of US$21.02 million and reduced basic loss per share from continuing operations of US$0.73 compared with US$1.94 a year earlier. At the same time, GeneDx reaffirmed its 2026 revenue outlook of US$540 million to US$555 million and highlighted FDA Breakthrough Device Designation plus a near-tripling of its sales force as it...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After 2025 Results And 2026 Revenue Guidance

Why Jazz Pharmaceuticals' latest earnings matter for shareholders Jazz Pharmaceuticals (JAZZ) has become a focus for investors after reporting fourth quarter and full year 2025 results, alongside 2026 revenue guidance, combining stronger quarterly earnings with a full year net loss profile. For the fourth quarter of 2025, Jazz Pharmaceuticals reported revenue of US$1,197.93 million compared with US$1,088.17 million a year earlier, while net income was US$203.45 million compared with US$191.12...